NEEDHAM, Mass., Aug. 3, 2026
Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating aglatimagene besadenovec in localized prostate cancer has been accepted for presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26–30, 2026, in Boston, Massachusetts. The presentation will highlight extended analyses using quantitative digital pathology to further characterize immune activation following treatment with the company’s investigational multimodal immunotherapy.
ASTRO 2026 Presentation Highlights Immune Activation Findings
The accepted poster, titled “Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer,” will be presented by Francesca Barone, M.D., Ph.D., Chief Scientific Officer of Candel Therapeutics, during the Genitourinary Cancer, Gynecological Cancer and Health Care Access and Engagement poster session on September 29, 2026. The presentation will provide additional insights into immune activation observed following treatment with aglatimagene besadenovec, expanding upon results from the company’s pivotal Phase 3 study in localized prostate cancer.
Phase 3 Program Builds on FDA-Recognized Immunotherapy Platform
Aglatimagene besadenovec is Candel Therapeutics’ lead investigational candidate developed using its genetically modified adenoviral immunotherapy platform. The therapy previously completed a pivotal placebo-controlled Phase 3 trial in localized prostate cancer conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA), with results published in The Lancet Oncology. The investigational therapy has also received FDA Fast Track Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation for newly diagnosed intermediate- to high-risk localized prostate cancer, in addition to Fast Track Designation for non-small cell lung cancer (NSCLC) and both Fast Track and Orphan Drug Designations for pancreatic ductal adenocarcinoma (PDAC).
Advertisement
Candel Advances Broad Cancer Immunotherapy Pipeline
Beyond aglatimagene besadenovec, Candel Therapeutics continues expanding its oncology pipeline through multiple viral immunotherapy platforms. The company’s HSV-based candidate linoserpaturev is currently being evaluated in an ongoing Phase 1b trial for recurrent high-grade glioma, while its proprietary enLIGHTEN™ Discovery Platform is advancing the development of next-generation viral immunotherapies for solid tumors. The upcoming ASTRO 2026 presentation is expected to provide additional evidence supporting the immunological mechanism of aglatimagene besadenovec and further strengthen its clinical development program for localized prostate cancer.
Source: Candel Therapeutics,press release
